A protein known as SORLA appears to defend neurons against tau tangles, the twisted protein clumps that accumulate inside nerve cells in Alzheimer's disease. Scientists at Sanford Burnham Prebys reported the finding on July 17, 2026, in the journal Science Advances, and they suggest that treatments designed to strengthen this protective capacity could eventually follow.
Tau is not a villain by nature. In a healthy brain, tau proteins hold the microtubule filaments inside neurons in shape, keeping the wiring of the nervous system structurally sound. Trouble begins when tau proteins clump together within nerve cells and form tangles, which are tied to cognitive decline and neuronal death across a family of disorders called tauopathies. Alzheimer's is the most familiar of these, but it is far from the only one.
That shared mechanism is what makes the SORLA result worth watching. A protein that limits tau-related damage would in principle be relevant beyond Alzheimer's, to other tauopathies that currently have no disease-modifying options. It also points research in a different direction than the field's long focus on clearing harmful proteins: instead of removing the tangles, the aim would be to reinforce the brain's own defenses against them.
This is early-stage laboratory science, and the researchers themselves frame it as a foundation for future work rather than a therapy in hand. Any drug that boosts SORLA activity would need years of additional testing before it reached patients.